Alcohol Septal Ablation and Pacemaker Implantation: Results After 5 Years

Alcohol septal ablation is used to treat patients with obstructive hypertrophic cardiomyopathy. A significant complication in this intervention is atrioventricular block requiring pacemaker implantation in 7% to 20% of cases. Current evidence is limited for clinical results at follow-up for these patients.

Ablación septal con alcohol e implante de marcapasos

The aim of this study was to evaluate the results for patients with permanent pacemaker implantation related to high-degree atrioventricular block.

The EURO-ASA multinational registry was used. A total of 1814 patients with 5 years of follow-up were analyzed. Within 30 days after ablation, 9.4% (170 patients) had a pacemaker implanted. 

After, propensity score matching was conducted to homogenize groups, and 278 patients were compared (139 pacemaker arm vs. 139 non-pacemaker arm). There were no long-term differences in terms of functional class and survival. 

However, patients in the pacemaker arm presented a lower long-term left ventricular (LV) outflow tract gradient (p < 0.01), a more pronounced decrease in LV gradient (p < 0.01), lower ejection fraction (= 0.02), and lower rates of reintervention (ablation or surgery) (p = 0.02).

Read also: Prognosis After Pacemaker Implantation in Alcohol Septal Ablation.

In multivariate analysis, older age (p < 0.01) and branch block prior to ablation (p = 0.01) were predictors of all-cause mortality.

Conclusion

Patients with hypertrophic cardiomyopathy treated with alcohol septal ablation had about a 9-% likelihood of pacemaker implantation within 30 days of the procedure. In the long term, patients who underwent pacemaker implantation had lower LV outflow tract gradient, greater steep decline in LV outflow tract gradient, lower ejection fraction, and lower rates of reintervention. However, they had similar survival rates and functional class compared with patients who did not undergo pacemaker implantation.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation.

Reference: Josef Veselka, MD et al J Am Coll Cardiol Intv 2022;15:1910–1917.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...